Shire launches ADHD tech challenge

Share this article:

Taking a page from Sanofi, Shire is preparing to launch a developer challenge “to create technology driven solutions that aid individuals with ADHD during the transition from adolescence into adulthood.”

The company's two-stage Shire ADHD Transitions Challenge will shower $150,000 in awards on eight teams of developers. The overall winner will take home $100,000 and score two tickets to the Fall 2013 Health 2.0 conference, where their win will be announced.

Judges will be looking for tools that help ADHD patients manage transitions – such as those from high school to the less-structured environment of college life, or from college to the workforce – as well as addressing everyday organizational and life management challenges and encouraging medication adherence. For the first phase of the challenge (submissions are due by March 17), teams will submit a five-page plan. In the second phase, five finalist teams will execute on their plans.  

A 2007 survey suggests that almost 10% of US children and 4.4% of adults are affected by ADHD, for which Shire markets Adderall XR, Intuniv and Vyvanse.

Shire's contest is reminiscent of Sanofi's Data Design Diabetes and Collaborate | Activate challenges, for technology to help diabetes patients and patient advocacy groups, respectively.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.